keyword
MENU ▼
Read by QxMD icon Read
search

adenomas radiotherapy

keyword
https://www.readbyqxmd.com/read/27926659/macroprolactinomas-and-nonfunctioning-pituitary-adenomas-and-pregnancy-outcomes
#1
Kimberley Lambert, Kate Rees, Paul T Seed, Mandish K Dhanjal, Marian Knight, David R McCance, Catherine Williamson
OBJECTIVE: To examine the monitoring, management, and outcomes of pituitary tumors in pregnancy. METHODS: A national, prospective, observational, population-based case series study was conducted in all U.K. consultant-led obstetric units over 3 years using the U.K. Obstetric Surveillance System. To evaluate rates of adverse pregnancy outcomes, women with a macroprolactinoma (10 mm or greater) or nonfunctioning pituitary adenoma, diagnosed before or during pregnancy, were compared with two comparison groups: 1) a U...
December 2, 2016: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/27894339/the-identification-of-human-pituitary-adenoma-initiating-cells
#2
Branavan Manoranjan, Sujeivan Mahendram, Saleh A Almenawer, Chitra Venugopal, Nicole McFarlane, Robin Hallett, Thusyanth Vijayakumar, Almunder Algird, Naresh K Murty, Doron D Sommer, John P Provias, Kesava Reddy, Sheila K Singh
Classified as benign central nervous system (CNS) tumors, pituitary adenomas account for 10% of diagnosed intracranial neoplasms. Although surgery is often curative, patients with invasive macroadenomas continue to experience significant morbidity and are prone to tumor recurrence. Given the identification of human brain tumor-initiating cells (TICs) that initiate and maintain tumor growth while promoting disease progression and relapse in multiple CNS tumors, we investigated whether TICs also drive the growth of human pituitary adenomas...
November 28, 2016: Acta Neuropathologica Communications
https://www.readbyqxmd.com/read/27894193/currently-used-and-investigational-drugs-for-cushing%C3%A2-s-disease
#3
Denis Ciato, Aizhar G Mumbach, Marcelo Paez-Pereda, Günter K Stalla
Cushing's disease (CD) is caused by a corticotroph adenoma of the pituitary gland that secretes excess adrenocorticotropic hormone (ACTH) causing increased morbidity and mortality. Surgery is the treatment of choice, but is not always successful. Alternatives include radiotherapy, adrenal surgery, and pharmaceutical therapy. The latter is increasingly gaining momentum due to the recent development of compounds that reduce hypercortisolaemia or its symptoms, acting through different mechanisms. Areas covered: In this article, the authors provide a complete overview of the treatment options for Cushing´s disease, including adrenal-directed, tumor-targeted, and peripheral therapies that are currently used or in development, and discuss their potential advantages and limitations...
December 8, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27893664/genetic-aspects-of-pituitary-carcinoma-a-systematic-review
#4
Zijiang Yang, Ting Zhang, Heng Gao
BACKGROUND: Pituitary carcinoma (PC) is a rare type of malignant intracranial neoplasm defined as distant metastasis of pituitary adenoma (PA). Although PC incidence is low because only 0.1% to 0.2% of PAs ultimately develop into PCs, the prognosis is poor and 66% of patients die within the first year. Existing therapeutic measures, including surgical removal, chemotherapy, and radiotherapy, have limited effectiveness. The lack of efficacy of current treatments is largely caused by the limited understanding of the molecular pathogenesis of PA and the malignant transformation to PC...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27859437/characteristics-and-outcome-of-surgically-treated-pituitary-tumours-in-south-africa-a-single-centre-experience
#5
Khaled K Elmezughi, Fraser J Pirie, Ayesha A Motala
AIMS: To describe the clinical, biochemical, radiological and histological features and to determine the outcome of all patients with pituitary tumours treated surgically at Inkosi Albert Luthuli Central Hospital in Durban over a 5 year period. RESEARCH DESIGN: Retrospective chart review from 2008 to 2012. Clinical, biochemical and radiologic data were collected before and one year after surgery. Histopathology findings and peri-operative complications were recorded...
November 12, 2016: Clinical Endocrinology
https://www.readbyqxmd.com/read/27857869/endoscopic-transmaxillary-transposition-of-temporalis-flap-for-recurrent-cerebrospinal-fluid-leak-closure
#6
Regi Thomas, Shabari Girishan, Ari George Chacko
Objective To describe the technique of endoscopic transmaxillary temporalis muscle flap transposition for the repair of a persistent postoperative sphenoidal cerebrospinal fluid leak. Design The repair of a recurrent cerebrospinal fluid leak for a patient who had undergone endoscopic transsphenoidal excision of an invasive silent corticotroph Hardy C and Knosp Grade IV pituitary adenoma was undertaken. The patient had completed postoperative radiotherapy for the residual tumor and presented with cerebrospinal fluid leak, 1 year later...
December 2016: Journal of Neurological Surgery. Part B, Skull Base
https://www.readbyqxmd.com/read/27855233/a-macroprolactinoma-becoming-resistant-to-cabergoline-and-developing-atypical-pathology
#7
Emilia Sbardella, George Farah, Ahmed Fathelrahman, Simon Cudlip, Olaf Ansorge, Niki Karavitaki, Ashley B Grossman
: Pituitary adenomas are a common intracranial neoplasm, usually demonstrating a benign phenotype. They can be classified according to pathological, radiological or clinical behaviour as typical, atypical or carcinomas, invasive or noninvasive, and aggressive or nonaggressive. Prolactinomas account for 40-60% of all pituitary adenomas, with dopamine agonists representing the first-line treatment and surgery/radiotherapy reserved for drug intolerance/resistance or in neuro-ophthalmological emergencies...
2016: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/27821077/a-case-series-of-intestinal-adenomatous-polyposis-of-unidentified-etiology-a-late-effect-of-irradiation
#8
Lisanne Sara Rigter, Frank G J Kallenberg, Barbara Bastiaansen, Theo A M van Os, Floor E van Leeuwen, Monique Esther van Leerdam, Evelien Dekker
BACKGROUND: In a large number of patients with multiple gastrointestinal adenomatous polyps, no causal germline mutation can be found. Non-genetic factors may contribute to the development of adenomatous polyps in these unexplained polyposis patients. In the development of gastrointestinal cancer, prior exposure to abdominal radiotherapy has been identified as such a factor, as it increases the gastrointestinal cancer risk in cancer survivors. A relationship of radiotherapy with intestinal polyposis, however, has not yet been described...
November 8, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27806336/dosimetric-impact-of-multileaf-collimator-leaf-width-according-to-sophisticated-grade-of-technique-in-the-imrt-and-vmat-planning-for-pituitary-adenoma-lesion
#9
Soo-Min Chae, Ki Woong Lee, Seok Hyun Son
We analyzed the difference in the dosimetric effect between 5-mm and 2.5-mm multileaf collimator (MLC) leaf width according to the sophisticated grades of intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT). Nineteen patients with pituitary adenomas were selected for this study. The treatment plans were performed according to the size of the MLC (5-mm and 2.5-mm MLC), the type of technique (IMRT and VMAT), and the sophisticated grades of each technique (5-field, 9-field, 13-field, 17-field technique in IMRT and 1-arc and 2-arc techniques in VMAT)...
October 28, 2016: Oncotarget
https://www.readbyqxmd.com/read/27793123/invasive-myoepithelial-carcinoma-ex-pleomorphic-adenoma-of-the-major-salivary-gland-two-case-reports
#10
Takahiro Wakasaki, Marie Kubota, Yutaka Nakashima, Eri Tomonobe, Takenao Mihara, Junichi Fukushima
BACKGROUND: Myoepithelial carcinoma (MEC) is a rare salivary gland tumor. Its long-term prognosis remains unknown because of the paucity of reported cases with long-term follow-up. Although some case series exist, the clinical features of MEC vary considerably depending on the site of origin. Therefore, accumulation of these rare cases is important. CASE PRESENTATION: Case 1: An 89-year-old man presented with a 10-year history of a mass originating from the right parotid gland and involving the neck...
October 28, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27791524/reoperative-endoscopic-endonasal-surgery-for-residual-or-recurrent-pituitary-adenomas
#11
Hazem M Negm, Rafid Al-Mahfoudh, Manish Pai, Harminder Singh, Salomon Cohen, Sivashanmugam Dhandapani, Vijay K Anand, Theodore H Schwartz
OBJECTIVE Regrowth of the lesion after surgical removal of pituitary adenomas is uncommon unless subtotal resection was originally achieved in the first surgery. Treatment for recurrent tumor can involve surgery or radiotherapy. Locations of residual tumor may vary based on the original approach. The authors evaluated the specific sites of residual or recurrent tumor after different transsphenoidal approaches and describe the surgical outcome of endoscopic endonasal transsphenoidal reoperation. METHODS The authors analyzed a prospectively collected database of a consecutive series of patients who had undergone endoscopic endonasal surgeries for residual or recurrent pituitary adenomas after an original transsphenoidal microscopic or endoscopic surgery...
October 28, 2016: Journal of Neurosurgery
https://www.readbyqxmd.com/read/27743172/time-trends-of-mortality-in-patients-with-non-functioning-pituitary-adenoma-a-swedish-nationwide-study
#12
Daniel S Olsson, Ing-Liss Bryngelsson, Oskar Ragnarsson
PURPOSE: Patients with non-functioning pituitary adenomas (NFPA), especially women, have increased mortality. The aim of this study was to investigate whether mortality in NFPA patients has changed during the last two decades. METHODS: This was a nationwide population-based study including 2795 patients (1502 men, 1293 women) diagnosed with NFPA between 1997 and 2011. Patients were identified and followed in Swedish National Health Registries. Standardized mortality ratios (SMRs) with 95 % confidence intervals were calculated for three time periods at first NFPA diagnosis using the general population as reference...
October 14, 2016: Pituitary
https://www.readbyqxmd.com/read/27729088/target-delineation-and-optimal-radiosurgical-dose-for-pituitary-tumors
#13
Giuseppe Minniti, Mattia Falchetto Osti, Maximillian Niyazi
Stereotactic radiosurgery (SRS) delivered as either single-fraction or multi-fraction SRS (2-5 fractions) is frequently employed in patients with residual or recurrent pituitary adenoma. The most common delivery systems used for SRS include the cobalt-60 system Gamma Knife, the CyberKnife (CK) robotic radiosurgery system, or a modified conventional radiotherapy machine (linear accelerator, LINAC). Tumor control and normalization of hormone hypersecretion have been reported in 75-100 % and 25-80 % of patients, respectively...
October 11, 2016: Radiation Oncology
https://www.readbyqxmd.com/read/27709409/radiation-induced-gliomas-a-comprehensive-review-and-meta-analysis
#14
Ryuya Yamanaka, Azusa Hayano, Tomohiko Kanayama
By conducting a systemic search of the PubMed database, we performed a comprehensive literature review to characterize secondary gliomas following radiotherapy treatment and to determine the most appropriate treatment strategy. Our analysis included 296 cases of radiation-induced gliomas. The primary lesion was characterized as a hematological malignancy in 104 cases (35.1 %), pituitary adenoma in 35 (11.8 %), craniopharyngioma in 19 (6.4 %), medulloblastoma in 38 (12.8 %), germ cell tumor in 13 (4.3 %), low-grade glioma in 28 (9...
October 5, 2016: Neurosurgical Review
https://www.readbyqxmd.com/read/27635963/congress-of-neurological-surgeons-systematic-review-and-evidence-based-guideline-for-the-management-of-patients-with-residual-or-recurrent-nonfunctioning-pituitary-adenomas
#15
Jason Sheehan, Cheng-Chia Lee, Mary E Bodach, Luis M Tumialan, Nelson M Oyesiku, Chirag G Patil, Zachary Litvack, Gabriel Zada, Manish K Aghi
BACKGROUND: Despite the advancement of microsurgical and endoscopic techniques, some nonfunctioning pituitary adenomas (NFPAs) can be difficult to cure. Tumor recurrence or incomplete resection may occur in some patients with NFPAs, and management strategies for these NFPAs remain unclear. OBJECTIVE: To review the existing literature as it pertains to the management of postsurgical residual or recurrent NFPAs. METHODS: A systematic review of the treatment options for residual or recurrent NFPAs was performed...
October 2016: Neurosurgery
https://www.readbyqxmd.com/read/27605481/-primary-pituitary-malignant-lymphoma-that-was-difficult-to-differentiate-from-nonfunctioning-pituitary-adenoma-a-case-report
#16
Yuta Murakami, Taku Sato, Shinya Jinguji, Yugo Kishida, Tadashi Watanabe, Osamu Suzuki, Kazuhiko Ikeda, Miyuki Homma, Sanae Midorikawa, Kiyoshi Saito
We report a rare case of primary pituitary lymphoma in a 75-year-old immunocompetent woman. The patient was blind in the right eye and presented with visual disturbance in the left eye that started 2 months previously. She also exhibited right third and fifth cranial nerve palsy. Magnetic resonance imaging(MRI)revealed an intrasellar mass lesion with right cavernous sinus invasion and suprasellar extension with compression of the optic chiasm. The mass lesion was isointense on both T1WI and T2WI, and showed less enhancement than a normal pituitary gland on gadolinium-enhanced T1WI...
September 2016: No Shinkei Geka. Neurological Surgery
https://www.readbyqxmd.com/read/27600151/pituitary-tumors-in-men1-do-not-be-misled-by-borderline-elevated-prolactin-levels
#17
Alina Livshits, Jelena Kravarusic, Ellie Chuang, Mark E Molitch
PURPOSE: The objective of this case report is to demonstrate that the simple expedient of measuring periodic prolactin levels in patients with MEN1 who have modest hyperprolactinemia and normal pituitary MRI scans is insufficient to monitor for the development of pituitary adenomas. METHODS: Review of relevant literature and chart review. RESULTS: A 25 year old man with known MEN1 manifested by hyperparathyroidism and a gastrin-producing neuroendocrine tumor was found to have a prolactin [PRL] level of 20...
December 2016: Pituitary
https://www.readbyqxmd.com/read/27581836/how-effective-is-temozolomide-for-treating-pituitary-tumours-and-when-should-it-be-used
#18
Carmel Halevy, Benjamin C Whitelaw
Temozolomide (TMZ) has been shown as an effective treatment option in aggressive pituitary adenomas and carcinomas. This review analyses the published case series and demonstrates 42 % of patents show a radiological response and 27 % experience stable disease following TMZ. Prolactinomas and corticotroph tumours respond best to TMZ, showing approximately a 50 % response rate, with non-functioning tumours responding only half as frequently. Other factors that may predict the tumour's TMZ response include MGMT and MSH status, but neither is sufficiently robust to determine treatment decisions...
August 31, 2016: Pituitary
https://www.readbyqxmd.com/read/27562400/successful-treatment-of-residual-pituitary-adenoma-in-persistent-acromegaly-following-localisation-by-11c-methionine-pet-co-registered-with-mri
#19
Olympia Koulouri, Narayanan Kandasamy, Andrew C Hoole, Daniel Gillett, Sarah Heard, Andrew S Powlson, Dominic G O'Donovan, Anand K Annamalai, Helen L Simpson, Scott A Akker, Simon J B Aylwin, Antonia Brooke, Harit Buch, Miles J Levy, Niamh Martin, Damian Morris, Craig Parkinson, James R Tysome, Tom Santarius, Neil Donnelly, John Buscombe, Istvan Boros, Rob Smith, Franklin Aigbirhio, Nagui M Antoun, Neil G Burnet, Heok Cheow, Richard J Mannion, John D Pickard, Mark Gurnell
OBJECTIVE: To determine if functional imaging using (11)C-methionine positron emission tomography co-registered with 3D gradient echo MRI (Met-PET/MRI), can identify sites of residual active tumour in treated acromegaly, and discriminate these from post-treatment change, to allow further targeted treatment. DESIGN/METHODS: Twenty-six patients with persistent acromegaly after previous treatment, in whom MRI appearances were considered indeterminate, were referred to our centre for further evaluation over a 4...
November 2016: European Journal of Endocrinology
https://www.readbyqxmd.com/read/27523417/-radiotherapy-of-benign-intracranial-tumors
#20
M Delannes, I Latorzeff, M E Chand, A Huchet, C Dupin, P Colin
Most of the benign intracranial tumors are meningiomas, vestibular schwannomas, pituitary adenomas, craniopharyngiomas, and glomus tumors. Some of them grow very slowly, and can be observed without specific treatment, especially if they are asymptomatic. Symptomatic or growing tumors are treated by surgery, which is the reference treatment. When surgery is not possible, due to the location of the lesion, or general conditions, radiotherapy can be applied, as it is if there is a postoperative growing residual tumor, or a local relapse...
September 2016: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
keyword
keyword
74547
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"